Table 1.
Main baseline demographic and clinical characteristics of patients in the training set and validation set
| Characteristic | Training set (n = 48) | Validation set (n = 12) | P-value |
|---|---|---|---|
| Sex | 0.998 | ||
| Male | 41 (85) | 10 (83) | |
| Female | 7 (15) | 2 (17) | |
| Median age (y)* | 49 (31-66) | 49 (36-59) | 0.318 |
| Median BMI (kg/m2)* | 21.9 (18.3-28.7) | 23.5 (18.4-27.9) | 0.134 |
| Cause of disease | 0.997 | ||
| Chronic hepatitis B only | 43 (90) | 11 (92) | |
| Unknown | 5 (10) | 1 (8) | |
| Child-Pugh class | |||
| A | 41 (85) | 9 (75) | 0.861 |
| B | 7 (15) | 3 (25) | |
| ECOG performance status | 0.862 | ||
| 0 | 7 (15) | 1 (8) | |
| 1 | 36 (75) | 8 (67) | |
| 2 | 5 (10) | 3 (25) | |
| HCC type | 0.717 | ||
| Nodular | 23 (48) | 8 (67) | |
| massive | 25 (52) | 4 (33) | |
| Median tumor size (mm) | 79 (32-160) | 60 (35-121) | 0.018# |
| Macroscopic vascular invasion | 28 (58) | 6 (50) | 0.965 |
| Extrahepatic spread | 30 (63) | 7 (58) | 0.995 |
| Biochemical analysis* | |||
| Median albumin level (g/dL) | 37 (25-45) | 34 (31-39) | 0.017# |
| Median total bilirubin level (mg/dL) | 16 (6-41) | 19 (10-101) | 0.216 |
| Median ɑ-fetoprotein level (ng/mL) | 760 (1-84500) | 336 (3-72814) | 0.419 |
| Median survival end points (d)* | |||
| Overall survival | 480 (90-1975) | 570 (180-1468) | 0.496 |
| Time to progression | 240 (30-1006) | 275 (60-458) | 0.280 |
Note: Except where indicated, data are numbers of patients, with percentages in parentheses. BMI: body mass index, ECOG: Eastern Cooperative Oncology Group, HCC: hepatocellular carcinoma;
*Numbers in parentheses are ranges;
#Statistically significant.